Compassionate Use or Expanded Access of Dupilumab

Regeneron Pharmaceuticals

Overview

Provide Compassionate Use or Expanded Access of Dupilumab

Compassionate Use or Expanded Access requests are only being considered in response to Individual Patient or Treatment Investigational New Drug (IND) applications. Availability will depend on location.

Study Type

EXPANDED_ACCESS

Conditions

Type 2 Inflammatory Disorders

Interventions

DupilumabDRUG

To be provided by Regeneron

Eligibility

Sex: ALLMin age: 6 Months

Medical Language ↔ Plain English

Eligibility will be determined during the application review process.

Central Contacts

Requests must be initiated by a treating physician. Physicians should contact

CONTACT

844-734-6643 compassionateuserequests@regeneron.com

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.